Success and Challenges in the Management of Chronic Myeloid Leukemia
Open Access
- 1 July 2019
- journal article
- review article
- Published by Georg Thieme Verlag KG in Annals of the National Academy of Medical Sciences (India)
- Vol. 55 (03), 135-137
- https://doi.org/10.1055/s-0039-1698546
Abstract
Chronic myeloid leukemia (CML) is one of the most common myeloproliferative neoplasms characterized by the presence of Philadelphia chromosome, that is, t(9:22), a reciprocal translocation between long arms of chromosomes 9 and 22. In its natural course CML has three phases, that is, chronic phase, accelerated phase, and blast crises phase. Peripheral blood shows marked leukocytosis and left shift. Diagnosis is confirmed by demonstration of specific molecular abnormality by polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH) method or cytogenetics. The drug of choice is tyrosine kinase inhibitor (TKI); imatinib. Other TKIs are dasatinib and nilotinib. Most patients respond and have almost normal life span. However, challenges remain. At present the drug is prescribed for lifelong. Recent studies have shown that the drug may be stopped in certain groups of which around 50% remain in long term remission (operational cure). However, around 20% did not respond and showed resistance. Research is in progress to find out the mechanism of resistance and newer therapeutic modalities or agents.Keywords
This publication has 8 references indexed in Scilit:
- Mutation Analysis in Chronic Myeloid Leukemia Patient in Chronic Phase on Imatinib Having Delayed Achievement of Milestones or Loss of ResponseIndian Journal of Hematology and Blood Transfusion, 2016
- Chronic myeloid leukemia data from IndiaIndian Journal of Medical and Paediatric Oncology, 2013
- Alterations in the Circulating Nitrite Levels and Expression of NOS Isoforms in the Neutrophils of AML PatientsBlood, 2012
- Genetic polymorphism of CYP3A5 in Indian chronic myeloid leukemia patientsMolecular and Cellular Biochemistry, 2009
- S-phase fraction as response marker in patients with chronic myeloid leukemiaLeukemia & Lymphoma, 2009
- Oxidative stress and antioxidant status in patients with chronic myeloid leukemiaIndian Journal of Clinical Biochemistry, 2008
- Increased frequencies of glutathione-S-transferase (GSTM1 and GSTT1) null genotypes in Indian patients with chronic myeloid leukemiaLeukemia Research, 2007
- Imatinib Mesylate — A New Oral Targeted TherapyThe New England Journal of Medicine, 2002